Daniel Shevrin
Overview
Explore the profile of Daniel Shevrin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller C, et al.
Clin Cancer Res
. 2024 Aug;
30(19):4318-4328.
PMID: 39115414
Purpose: Deleterious germline/somatic homologous recombination repair mutations (HRRm) are present in ∼25% of patients with metastatic castration-resistant prostate cancer (mCRPC). Preclinically, poly(ADP-ribose) polymerase (PARP) inhibition demonstrated synergism with androgen receptor...
2.
Aggarwal R, Heller G, Hillman D, Xiao H, Picus J, Taplin M, et al.
J Clin Oncol
. 2024 Jan;
42(10):1114-1123.
PMID: 38261983
Purpose: Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, and abiraterone...
3.
Morgans A, Chen Y, Jarrard D, Carducci M, Liu G, Eisenberger M, et al.
Prostate
. 2022 May;
82(12):1176-1185.
PMID: 35538398
Background: E3805 (CHAARTED) is a phase 3 trial demonstrating improved survival for men with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to treatment with docetaxel (D) and androgen-deprivation therapy (ADT) versus ...
4.
Serritella A, Shevrin D, Heath E, Wade J, Martinez E, Anderson A, et al.
Clin Cancer Res
. 2022 Feb;
28(8):1549-1559.
PMID: 35110415
Purpose: Although androgen deprivation therapy (ADT) and androgen receptor (AR) signaling inhibitors are effective in metastatic prostate cancer, resistance occurs in most patients. This phase I/II trial assessed the safety,...
5.
Flanders S, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, et al.
Future Oncol
. 2018 Feb;
14(6):527-536.
PMID: 29417827
Aim: To validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients. Patients & Methods: Baseline comorbidity scores collected using the TIBI-CaP were compared...
6.
Harshman L, Chen Y, Liu G, Carducci M, Jarrard D, Dreicer R, et al.
J Clin Oncol
. 2017 Dec;
36(4):376-382.
PMID: 29261442
Purpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial comparing androgen-deprivation therapy (ADT) plus docetaxel with ADT alone...
7.
Vaishampayan U, Shevrin D, Stein M, Heilbrun L, Land S, Stark K, et al.
Urology
. 2015 Sep;
86(6):1206-11.
PMID: 26375845
Objective: To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in...
8.
Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisenberger M, et al.
N Engl J Med
. 2015 Aug;
373(8):737-46.
PMID: 26244877
Background: Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer...
9.
Pascal L, Masoodi K, OMalley K, Shevrin D, Gingrich J, Parikh R, et al.
J Urol
. 2014 Dec;
193(4):1388-93.
PMID: 25444984
Purpose: Intermittent androgen deprivation therapy in patients with prostate specific antigen progression after localized prostate cancer treatment is an alternative to standard continuous androgen deprivation therapy. Intermittent androgen deprivation therapy...
10.
Dreicer R, MacLean D, Suri A, Stadler W, Shevrin D, Hart L, et al.
Clin Cancer Res
. 2014 Jan;
20(5):1335-44.
PMID: 24418642
Purpose: The androgen receptor pathway remains active in men with prostate cancer whose disease has progressed following surgical or medical castration. Orteronel (TAK-700) is an investigational, oral, nonsteroidal, selective, reversible...